Experimental veterinary SARS-CoV-2 vaccine cross neutralization of the Delta (B.1.617.2) variant virus in cats고양이에서 델타(B.1.617.2) 변이 바이러스의 실험적 수의사 SARS-CoV-2 백신 교차 중화Article Published on 2022-05-012022-09-11 Journal: Veterinary microbiology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antibody B.1.617.2 Canidae canine Canine vaccine Cat vaccine characterized comparable cross Delta delta variant epidemiological exhibited Felidae Hominidae immune response Mammalia mink Mink vaccine mounted Mutation neutralization neutralize novel Pathogenesis produced reduced reporter robust SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike protein SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 Wuhan strain serum Serum Neutralization Spike protein the SARS-CoV-2 Transmissibility Transmission vaccination Vaccine variant variant B.1.617.2 variety Veterinary vaccine virus Wuhan strain Zoetis Zoetis. [DOI] 10.1016/j.vetmic.2022.109395 PMC 바로가기 [Article Type] Article
Aerosol exposure of staff during dental treatments: a model study치과 치료 중 직원의 에어로졸 노출: 모델 연구Article Published on 2022-04-152022-09-11 Journal: BMC Oral Health [Category] COVID19(2023년), SARS, 치료기술, [키워드] aerosol aerosol exposure Aerosols ANOVA COVID-19 dental Dental handpiece Dental staff Dental suction Dental unit disease Efficacy evaluate evaluated experiments exposure to high risk Laser mounted mouth oral Oral medicine Particle reduce Saliva SARS-CoV-2 significantly significantly increased spectrometer suction transmitted Treatment were measured were used [DOI] 10.1186/s12903-022-02155-9 PMC 바로가기 [Article Type] Article
Severe neonatal COVID-19: Challenges in management and therapeutic approach중증 신생아 COVID-19: 관리 및 치료적 접근의 도전Case Reports Published on 2022-04-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Adults age Bacterial biological samples breathing challenge Chest computed tomography chest X-rays children clearance clinical manifestation clinical manifestations complications Computed tomography consolidations contributed coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critical case critical cases demonstrated enoxaparin Enterobacter etiological agent immunomodulation increasingly Infant Infants intensive care interstitial interstitial pneumonia less life-threatening lung management mechanical ventilation mounted multidrug-resistant Neonatal Neonatal COVID-19 neonatal sepsis Neonate Neonates Older reported respiratory infection respiratory specimen respiratory specimens SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 RNA Sepsis serological test Serological tests Severe acute respiratory syndrome severe acute respiratory syndrome 2. severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Severe case steroid Steroids stools sustained Therapeutic approach viral replication Work of breathing [DOI] 10.1002/jmv.27472 PMC 바로가기 [Article Type] Case Reports
Humoral response to SARS-CoV-2 infection among liver transplant recipients간 이식 환자의 SARS-CoV-2 감염에 대한 체액 반응Multicenter Study Published on 2022-04-012022-09-11 Journal: Gut [Category] Coronavirus, COVID19(2023년), SARS, 치료기술, 치료법, [키워드] anti-S antibody antibody Antibody Response Antibody testing Antibody titre assigned B lymphocytes case-control study Cohort cohorts controls COVID-19 COVID-19 symptom COVID-19 symptoms criteria detectable expected functional humoral Humoral response immune immune response Immunosuppression Immunosuppressive agents interfere less liver liver transplant Liver transplantation majority mounted multicentre neutralising ability Neutralising activity no difference nucleocapsid protein Patient Prospective Protein recipient recipients required SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-COV-2 infection Serologic response significantly lower subject Symptoms Testing the antibody response with COVID-19 [DOI] 10.1136/gutjnl-2021-326609 PMC 바로가기 [Article Type] Multicenter Study
Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimodocrelizumab 및 fingolimod로 치료받은 다발성 경화증 환자에서 mRNA SARS-CoV-2 백신 접종에 대한 6개월 체액 반응Article Published on 2022-04-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] age analysed Analysis Antibody Units baseline BAU binding antibody unit binding antibody units BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine Clinical data collected correlation COVID-19 disease each time-point Efficacy elapsed expressed fingolimod first dose HCs healthy control humoral Humoral response IgG IgG antibodies IgG antibody immunological characteristics investigated long term Long term humoral response lymphocyte Lymphocyte count mounted mRNA mRNA vaccine Multiple multiple sclerosis NAb NAbs neutralizing antibody Ocrelizumab Patient positive positive correlation positive response preserved Quantitative receiving SARS-CoV-2 SARS-CoV-2 mRNA vaccine SARS-CoV-2 trimeric spike protein SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines sera serum sample serum samples significantly higher Spearman correlation coefficient Spike protein tested the disease the SARS-CoV-2 therapy titre treated Treatment Trimeric spike protein vaccination Vaccine weakened were assessed [DOI] 10.1016/j.msard.2022.103724 PMC 바로가기 [Article Type] Article
Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVID-19 vaccineBNT162b2 mRNA COVID-19 백신에 대한 신속한 반응과 관련된 혈소판 및 면역 신호Article Published on 2022-04-012022-09-12 Journal: Journal of thrombosis and haemostasis : JTH [Category] COVID19(2023년), SARS, 진단, [키워드] aggregates B cells Biomarker BNT162b2 BNT162b2 mRNA CD31 circulating platelet COVID-19 COVID-19 vaccine Critical cytokine response dose effective Efficacy elevated enrolled eosinophils expressed feature females first dose healthy volunteer humoral identify immune response immune signature immune system Immunity inhibitory leukocyte median motif mounted mRNA-based COVID-19 vaccine mRNA-based vaccine neutralizing antibody non-classical monocyte of BNT162b2 participant Platelet platelet activation Platelet count rapid immune response rapid response reactive receptor responders second dose stability stimulate the vaccine Vaccine Vaccines Vascular [DOI] 10.1111/jth.15648 PMC 바로가기 [Article Type] Article
Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factorsSARS-CoV-2 백신 접종 후 면역 약화 및 영향 요인 모델링Article Published on 2022-03-282022-09-12 Journal: Nature Communications [Category] MERS, SARS, 진단, [키워드] age antibody Antibody Response BNT162b2 vaccine ChAdOx1-nCoV19 Combination correlated COVID-19 cubic spline decrease determine dose examined Factor first dose Generalized IgA IgA response IgG IgG antibody IgG level Immunity Infection initial Injections knowledge modeling mounted natural infection of BNT162b2 responses SARS-CoV-2 SARS-CoV-2 vaccination second dose Sex significantly suggested T-cell T-cell Response Vaccine waning immunity were used [DOI] 10.1038/s41467-022-29225-4 PMC 바로가기 [Article Type] Article
Immune mechanisms associated with sex-based differences in severe COVID-19 clinical outcomesReview Published on 2022-03-042022-10-28 Journal: Biology of Sex Differences [Category] COVID-19, MERS, SARS, [키워드] acute respiratory syndrome Algorithm Antibody Response Biological Care cellular clinical decision Clinical outcome clinical outcomes contribute coronavirus coronavirus disease COVID-19 COVID-19 patient COVID-19 patients COVID-19 severity death develop disease dysregulated environmental factors Evidence explain expression facilitate faster fatality female females Gender Genetic Health help immune response immunologic response Inflammatory response male males mechanism Mild Mortality mounted outcome outcomes preventative measures Respiratory failure risk factor risk of infection robust SARS-CoV-2 SARS-COV-2 infection severe COVID-19 severe pneumonia severity Sex Therapies Treatment treatment strategy understanding with COVID-19 X inactivation [DOI] 10.1186/s13293-022-00417-3 PMC 바로가기 [Article Type] Review
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialCovid-19 (회복)로 병원에 입원 한 환자의 Casirivimab 및 Imdevimab : 무작위, 통제, 오픈 라벨, 플랫폼 시험Randomized Controlled Trial Published on 2022-02-122022-08-13 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료제, [키워드] (Medical Research Council 1:1 28-day mortality 95% CI Administered Adverse reaction Adverse reactions All participants all randomly assigned patients all-cause mortality Analysis antibody assigned baseline baseline antibody status bleeding Cardiac arrhythmia Casirivimab cause-specific mortality clinically suspected Combination death detectable died dose Efficacy Efficacy and safety eligible Eligible participants enrolled evaluate finding funding hospital host cells humoral immune response Imdevimab Innovation Intention intention to treat intravenous infusion investigator investigators ISRCTN laboratory-confirmed SARS-CoV-2 infection Local major bleeding events Medical Research Council monoclonal antibody monoclonal antibody combination Mortality mounted non-competing monoclonal antibodies non-competing monoclonal antibody Open-label outcome p value participant Patient Platform trial Primary outcome randomisation randomised randomised, controlled, open-label platform trial Randomly randomly assigned patient rate ratio Receptor binding domain recovery reduced Registered reported Safety SARS-COV-2 infection SARS-CoV-2 spike glycoprotein SARS-CoV-2 vaccine Serious adverse reactions seronegative seronegative patient seronegative patients seropositive seropositive and seronegative patients Seven significantly single intravenous infusion spike glycoprotein Standard of care the SARS-CoV-2 thrombosis Treatment Trial UK hospital usual care usual care alone Viral viral entry with COVID-19 [DOI] 10.1016/S0140-6736(22)00163-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation일반 감기 인간 코로나바이러스에 대한 COVID-19 이전 면역은 교차 중화 없이 SARS-CoV-2 항원에 대한 회수형 IgG 반응을 유도합니다Immunology Published on 2022-02-112022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgG antibody Antibody Response Cold common coronaviral infection coronavirus COVID-19 COVID-19 patient COVID-19 patients cross-protection de novo healthy donor Human humoral immune response IgA IgG IgG antibodies IgG response IgM IgM response in vitro indicated Intravenous immunoglobulin memory mounted neutralising Patient pre-existing immunity response responsible SARS-CoV-2 SARS-CoV-2 antigen sera the patient titre [DOI] 10.3389/fimmu.2022.790334 PMC 바로가기 [Article Type] Immunology